Publication:
Cannabinoids and neuroinflammation: Therapeutic implications

Simple item page
dc.contributor.authorARICIOĞLU, FEYZA
dc.contributor.authorsLeonard B. E., ARICIOĞLU F.
dc.date.accessioned2023-03-07T11:16:44Z
dc.date.available2023-03-07T11:16:44Z
dc.date.issued2023-04-01
dc.description.abstractThis review summarizes the pharmacological properties of tetrahydrocannabinol (THC) and cannabidiol (CBD), cannabinoid components of several species of herbal cannabis. The pharmacological effects of the phytocannabinoids have been extensively investigated and the importance of the cannabinoid receptors (CB1 and CB2) on immune cells has provided important information on the intracellular targets for these molecules. In addition to the phytocannabinoids, endogenous cannabinoids also exist in the form of anadramide and 2-srodolylglycerol (2-AG). These, together with their synthesizing and metabolizing enzymes, form the cannabinoid system. Since the discovery of the endocannabinoid system and the role that neuroinflammation plays in neurological and psychiatric illness, the potential therapeutic importance of this system has been of growing interest. In addition, the need to develop drugs which specifically target the CB1 and CB2 receptors has been stimulated by the pharmacological complexity of both THC and CBD. This review briefly summarizes the therapeutic potential of the naturally occurring and the synthetic cannabinoids which will need to be developed, if such drugs are to fulfill the therapeutic promise which the cannabinoids offer.
dc.identifier.citationLeonard B. E., ARICIOĞLU F., "Cannabinoids and neuroinflammation: Therapeutic implications", Journal of Affective Disorders Reports, cilt.12, 2023
dc.identifier.doi10.1016/j.jadr.2023.100463
dc.identifier.issn2666-9153
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85148344823&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/287281
dc.identifier.volume12
dc.language.isoeng
dc.relation.ispartofJournal of Affective Disorders Reports
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectSosyal ve Beşeri Bilimler
dc.subjectPsikoloji
dc.subjectKlinik Psikolojisi
dc.subjectSağlık Bilimleri
dc.subjectSocial Sciences and Humanities
dc.subjectPsychology
dc.subjectClinical Psychology
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectTemel Bilimler (SCI)
dc.subjectPsikiyatri
dc.subjectPSİKOLOJİ, KLİNİK
dc.subjectClinical Medicine (MED)
dc.subjectNatural Sciences (SCI)
dc.subjectPSYCHIATRY
dc.subjectPSYCHOLOGY
dc.subjectPSYCHOLOGY, CLINICAL
dc.subjectKlinik Psikoloji
dc.subjectSosyal Bilimler ve Beşeri Bilimler
dc.subjectPsikiyatri ve Ruh Sağlığı
dc.subjectSocial Sciences & Humanities
dc.subjectPsychiatry and Mental Health
dc.subjectanadamide and 2-AG
dc.subjectAnti-covid 19
dc.subjectendogenous cannabinoids
dc.subjectMicroglia
dc.subjectNeuroinflammation
dc.subjectPhytocannabinoids
dc.subjectTHC and CBD
dc.subjecttherapeutic potential
dc.titleCannabinoids and neuroinflammation: Therapeutic implications
dc.typearticle
dspace.entity.typePublication
local.avesis.id5a9f69cc-9faa-4f4e-8dbe-87e742714f78
local.indexed.atSCOPUS
relation.isAuthorOfPublicationa3c22d37-3fc1-4221-b0b3-ac9764a7b8b3
relation.isAuthorOfPublication.latestForDiscoverya3c22d37-3fc1-4221-b0b3-ac9764a7b8b3

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
16.pdf
Size:
7.78 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs